Data Show Significant Benefits With NxStage Home Dialysis Versus Peritoneal
Patients who regularly use home hemodialysis are less likely to die, be hospitalized or drop out of treatment than patients who receive peritoneal dialysis, according to a study by the Chronic Disease Research Group.
The study was funded by NxStage Medical, which makes the System One, the only portable hemodialysis system cleared by the FDA for home use. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients can use tap water to create dialysis fluid and require no special infrastructure to complete a treatment, the Lawrence, Mass., devicemaker says.
The CDRG study matched 4,460 home hemodialysis patients with 4,460 peritoneal dialysis patients. Those in the HHD group had a 13 percent lower risk of cardiovascular-related death and 20 percent lower risk of infection-related death. They were also less likely to be hospitalized for those diagnoses — 16 percent for heart-related events and 11 percent for infections, the study found.
Patients receiving HHD also reported being happier with their lives. "Our patients constantly tell us that home hemodialysis has significantly changed their lives for the better," says NxStage President Joseph Turk. "These findings present a compelling reason to further strengthen HHD programs and expand patient access to this life-changing therapy.”
The data is being presented at the American Society of Nephrology's Kidney Week 2014, Nov. 11-16, in Philadelphia. — Kellen Owings
Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct